OncoMatch/Clinical Trials/NCT04559217

68Ga-DOTATATE Neuroblastoma Imaging Pilot

Is NCT04559217 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Radiopharmaceutical 68Ga-DOTATATE for neuroblastoma.

Phase 2RecruitingCentre de recherche du Centre hospitalier universitaire de SherbrookeNCT04559217Data as of May 2026

Treatment: Radiopharmaceutical 68Ga-DOTATATE — Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET/CT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroblastoma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify